Ropivacaine extended release - PainReform

Drug Profile

Ropivacaine extended release - PainReform

Alternative Names: PRF 110; PRF-110-oily solution

Latest Information Update: 23 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PainReform
  • Class Amides; Local anaesthetics; Small molecules
  • Mechanism of Action Potassium channel antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Postoperative pain

Most Recent Events

  • 02 Jun 2016 PainReform plans a phase II trial for Postoperative pain in Israel (NCT02784327)
  • 15 Mar 2016 Biomarkers information updated
  • 23 Sep 2015 PainReform files for patent protection for PRF 110 and PG technology (PainReform's pipeline, September 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top